What is Alseres Pharmaceuticals, Inc. (ALSE) stock price today?

Alseres Pharmaceuticals, Inc. (ALSE) is currently trading at $0.01, up 100% today.

What is ALSE P/E ratio?

Alseres Pharmaceuticals, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ALSE return on equity (ROE)?

Alseres Pharmaceuticals, Inc.'s return on equity (ROE) is 5.04%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Alseres Pharmaceuticals, Inc.'s market cap?

Alseres Pharmaceuticals, Inc. has a market capitalization of $398255.

OTC · Biotechnology

Alseres Pharmaceuticals, Inc. (ALSE) Stock

$0.01 +100.00% OTC: ALSE Healthcare

Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system.

Valuation

Metric	Value
Price	$0.01
Market Cap	$398255
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.84
EPS (TTM)	$-153.67
52-Week High	$0.01
52-Week Low	$0.01
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	5.04%
ROA	-244.38%
ROCE	76.81%
Gross Margin	95.00%
Operating Margin	-204.76%
Net Margin	-198.85%
Debt/Equity	-0.73
Current Ratio	0.20

Annual Financials (USD)

Metric	2009	2010	2011	2012	2013
Revenue	$0	$0	$0	$1.0M	$0
Operating Profit	$-8.0M	$-3.0M	$-2.0M	$-1.0M	$-1.0M
Net Profit	$-11.0M	$1.0M	$-3.0M	$-2.0M	$-1.0M
EPS	$-2306.71	$81.12	$-486.45	$-268.56	$-153.67
Op Margin	—	—	—	-228.4%	-204.8%

Balance Sheet (USD)

Metric	2009	2010	2011	2012	2013
Total Assets	$1.0M	$0	$0	$1.0M	$0
Total Liabilities	$48.0M	$48.0M	$31.0M	$28.0M	$11.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$36.0M	$34.0M	$28.0M	$6.0M	$8.0M

Latest News

Alset AI Engages DS Market Solutions to Strengthen Market Liquidity and Support Shareholder Accessibility ACCESS Newswire · Jul 30, 2026 Alset AI Announces Closing of Third Tranche and Five-Year Maturity Extension of Loan Transaction ACCESS Newswire · Jul 21, 2026 Alset AI Announces Proposed Maturity Extension to Five Years and Update to Loan Transaction of up to $3 Million ACCESS Newswire · Jul 20, 2026 Alset AI Announces Closing of Shares for Debt Transaction ACCESS Newswire · Jul 8, 2026 Early Warning News Release Regarding the Disposition of Common Shares of Alset AI Ventures Inc. ACCESS Newswire · Jun 10, 2026

Cash Flow (USD)

Metric	2009	2010	2011	2012	2013
Operating Cash Flow	$-8.0M	$-3.0M	$-2.0M	$-1.0M	$-2.0M
Investing Cash Flow	$0	$0	$0	$0	$2.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$-8.0M	$-3.0M	$-2.0M	$-1.0M	$-2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-16.68
FCF Yield	-423.58%
Quick Ratio	0.20
Interest Coverage	-2.13
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHKFAchiko AG	$0.00	—	-0.04	$377400	0.00%
AGFAFDigicann Ventures Inc.	$0.00	—	0.00	$86599	0.00%
AQQRFAquarius Surgical Technologies Inc.	$0.00	—	-0.24	$115917	0.00%
ELVAYEvolva Holding S.A.	$1.16	+0.00%	-23.01	$518242	0.00%
FLURFFluroTech Ltd.	$0.00	—	-2.34	$447175	0.00%

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.

Alseres Pharmaceuticals, Inc. is headquartered in US.

Alseres Pharmaceuticals, Inc. (ALSE) stock trades at $0.01 with a market capitalization of $398255. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.84. Over the past 52 weeks the stock has ranged between $0.01 and $0.01, and currently trades at its 52-week high.

On profitability, Alseres Pharmaceuticals, Inc. generates a return on equity (ROE) of 5.04%, return on capital employed of 76.81%, an operating margin of -204.76%, a net profit margin of -198.85%.

Official website: www.alseres.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides